Toll-Like Receptors in Human Papillomavirus Infection

Ali RS, Falconer A, Ikram M et al (2001) Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J Invest Dermatol 117:106–111 Andersen JM, Al-Khairy D, Ingalls RR (2006) Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 74:824–831 Andonegui G, Bonder CS, Green F et al (2003) Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest 111:1011–1020 Bambou JC, Giraud A, Menard S et al (2004) In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem 279:42984–42992 Barak O, Treat JR, James WD (2005) Antimicrobial peptides: effectors of innate immunity in the skin. Adv Dermatol 21:357–374 Baranowski E, Ruiz-Jarabo CM, Domingo E (2001) Evolution of cell recognition by viruses. Science 292:1102–1105 Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257–263 Beutler BA (2009) TLRs and innate immunity. Blood 113:1399–1407 Biragyn A, Ruffini PA, Leifer CA et al (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025–1029 Bontkes HJ, Ruizendaal JJ, Kramer D et al (2005) Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 96:897–901 Brinkmann MM, Spooner E, Hoebe K et al (2007) The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 177:265–275 Buck CB, Day PM, Thompson CD et al (2006) Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA 103:1516–1521 Cao W, Zhang L, Rosen DB et al (2007) BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol 5:e248 Carpentier AF, Chen L, Maltonti F et al (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59:5429–5432 Chen XZ, Mao XH, Zhu KJ et al (2010) Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch Dermatol Res 302:57–65 Chen X, Wang S, Liu L et al (2012) A genetic variant in the promoter region of Toll-like receptor 9 and cervical cancer susceptibility. DNA Cell Biol 31:766–771 Chuang CM, Monie A, Wu A et al (2009) Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 20:303–313 Conner K, Nern K, Rudisill J et al (2002) The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J Am Acad Dermatol 47:347–350 Daud II, Scott ME, Ma Y et al (2011) Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 128:879–886 de Villiers EM, Fauquet C, Broker TR et al (2004) Classification of papillomaviruses. Virology 324:17–27 DeCarlo CA, Severini A, Edler L et al (2010) IFN-kappa, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Invest 90:1482–1491 DeCarlo CA, Rosa B, Jackson R et al (2012) Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012:785825 Didierlaurent AM, Morel S, Lockman L et al (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183:6186–6197 Einstein MH, Schiller JT, Viscidi RP et al (2009) Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9:347–356 El-Omar EM, Ng MT, Hold GL (2008) Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27:244–252 Fahey LM, Raff AB, Da Silva DM et al (2009) Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 182:2919–2928 Farshadpour F, Konings S, Speel EJ et al (2011) Human papillomavirus and oropharyngeal squamous cell carcinoma: a case-control study regarding tobacco and alcohol consumption. Pathol Res Int 2011:806345 Fausch SC, Da Silva DM, Rudolf MP et al (2002) Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 169:3242–3249 Feldman SA, Audet S, Beeler JA (2000) The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74:6442–6447 Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500–1510 Fulton C, Anderson GM, Zasloff M et al (1997) Expression of natural peptide antibiotics in human skin. Lancet 350:1750–1751 Funderburg N, Lederman MM, Feng Z et al (2007) Human beta-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 104:18631–18635 Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:710–720 Garcon N, Morel S, Didierlaurent A et al (2011) Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 25:217–226 Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8:594–606 Grimm C, Polterauer S, Natter C et al (2012) Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol 120:152–159 Hacker H, Redecke V, Blagoev B et al (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439:204–207 Hasan UA, Bates E, Takeshita F et al (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178:3186–3197 He B, Qiao X, Cerutti A (2004) CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173:4479–4491 Hemmi H, Akira S (2005) TLR signalling and the function of dendritic cells. Chem Immunol Allergy 86:120–135 Hirsch I, Caux C, Hasan U et al (2010) Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 31:391–397 Hofmann MA, Kors C, Audring H et al (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520–527 Honda K, Yanai H, Mizutani T et al (2004) Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 101:15416–15421 Honda K, Yanai H, Negishi H et al (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772–777 Hornef MW, Frisan T, Vandewalle A et al (2002) Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 195:559–570 Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995 Izaguirre A, Barnes BJ, Amrute S et al (2003) Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 74:1125–1138 Jang S, Park JS, Won YH et al (2012) The expression of Toll-like receptors (TLRs) in cultured human skin fibroblast is modulated by histamine. Chonnam Med J 48:7–14 Jiang Q, Wei H, Tian Z (2008) Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 8:12 Jin MS, Kim SE, Heo JY et al (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130:1071–1082 Joyce JG, Tung JS, Przysiecki CT et al (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810–5822 Karim R, Meyers C, Backendorf C et al (2011) Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 6:e17848 Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663 Kawai T, Sato S, Ishii KJ et al (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5:1061–1068 Khairuddin N, Gantier MP, Blake SJ et al (2012) siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 90:187–196 Kim HM, Park BS, Kim JI et al (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906–917 Kim WY, Lee JW, Choi JJ et al (2008a) Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 18:300–305 Kim YM, Brinkmann MM, Paquet ME et al (2008b) UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 452:234–238 Kjellberg L, Hallmans G, Ahren AM et al (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82(7):1332–1338 Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471–484 Kumar H, Kawai T, Akira S (2009a) Pathogen recognition in the innate immune response. Biochem J 420:1–16 Kumar H, Kawai T, Akira S (2009b) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388:621–625 Kundi M (2007) New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6:133–140 Kurt-Jones EA, Popova L, Kwinn L et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398–401 Lee JW, Choi JJ, Seo ES et al (2007) Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 46:941–947 Leonard JP, Link BK, Emmanouilides C et al (2007) Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin’s lymphoma. Clin Cancer Res 13:6168–6174 Liu H, Komai-Koma M, Xu D et al (2006) Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 103:7048–7053 Liu L, Botos I, Wang Y et al (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320:379–381 Lyakh LA, Koski GK, Telford W et al (2000) Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. J Immunol 165:3647–3655 Manches O, Munn D, Fallahi A et al (2008) HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 118:3431–3439 Mansilla C, Berraondo P, Durantez M et al (2012) Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int J Cancer 131:641–651 Martin M, Michalek SM, Katz J (2003) Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 71:2498–2507 Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449:819–826 Meyer-Hoffert U, Schwarz T, Schroder JM et al (2008) Expression of human beta-defensin-2 and -3 in verrucae vulgares and condylomata acuminata. J Eur Acad Dermatol Venereol 22:1050–1054 Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ et al (2008) Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111:4245–4253 Miller LS (2008) Toll-like receptors in skin. Adv Dermatol 24:71–87 Miller RL, Meng TC, Tomai MA (2008) The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21:69–87 Minami T, Kuroishi T, Ozawa A et al (2007) Histamine amplifies immune response of gingival fibroblasts. J Dent Res 86:1083–1088 Molling JW, de Gruijl TD, Glim J et al (2007) CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121:1749–1755 Moseman EA, Liang X, Dawson AJ et al (2004) Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells. J Immunol 173:4433–4442 Munger K, Baldwin A, Edwards KM et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–11460 Oganesyan G, Saha SK, Guo B et al (2006) Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439:208–211 Ohlschlager P, Spies E, Alvarez G et al (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128:473–481 O’Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353–364 Ospelt C, Brentano F, Rengel Y et al (2008) Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthr Rheum 58:3684–3692 Pandey S, Mittal RD, Srivastava M et al (2009) Impact of Toll-like receptors [TLR] 2 (−196 to −174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol 114:501–505 Pandey S, Mittal B, Srivastava M et al (2011) Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep 38:4715–4721 Park BS, Song DH, Kim HM et al (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:1191–1195 Pasare C, Medzhitov R (2004) Toll-like receptors and acquired immunity. Semin Immunol 16:23–26 Pichlmair A, Reis e Sousa C (2007) Innate recognition of viruses. Immunity 27:370–383 Rassa JC, Meyers JL, Zhang Y et al (2002) Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 99:2281–2286 Richards RM, Lowy DR, Schiller JT et al (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 103:1522–1527 Rock J, Schneider E, Grun JR et al (2007) CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2. Eur J Immunol 37:3564–3575 Roda JM, Parihar R, Carson WE III (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175:1619–1627 Roszak A, Lianeri M, Sowinska A et al (2012) Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development. Mol Biol Rep 39:8425–8430 Sato A, Iwasaki A (2004) Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc Natl Acad Sci USA 101:16274–16279 Schilling JD, Martin SM, Hung CS et al (2003) Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc Natl Acad Sci USA 100:4203–4208 Schlender J, Hornung V, Finke S et al (2005) Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol 79:5507–5515 Schneider V, Kay S, Lee HM (1983) Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 27:220–224 Schreibelt G, Tel J, Sliepen KH et al (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59:1573–1582 Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16:3–9 Taniguchi T, Takaoka A (2002) The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14:111–116 Thompson JA, Kuzel T, Drucker BJ et al (2009) Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 7:E58–E65 Tiberio L, Fletcher L, Eldridge JH et al (2004) Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 22:1515–1523 Tudor D, Dubuquoy C, Gaboriau V et al (2005) TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23:1258–1264 Tungteakkhun SS, Duerksen-Hughes PJ (2008) Cellular binding partners of the human papillomavirus E6 protein. Arch Virol 153:397–408 van Poelgeest MI, van Seters M, van Beurden M et al (2005) Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 11:5273–5280 van Seters M, van Beurden M, ten Kate FJ et al (2008) Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358:1465–1473 Visser J, Nijman HW, Hoogenboom BN et al (2007) Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 150:199–209 Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 Wang J, Hori K, Ding J et al (2011) Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol 226:1265–1273 Wu CY, Monie A, Pang X et al (2010) Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 17:88 Xu D, Komai-Koma M, Liew FY (2005) Expression and function of Toll-like receptor on T cells. Cell Immunol 233:85–89 Xu Y, Zhu KJ, Zhu N et al (2009) Expression of Foxp3+ CD4+ CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum. Clin Exp Dermatol 34:229–235 Yamamoto M, Sato S, Mori K et al (2002) Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169:6668–6672 Yamamoto M, Sato S, Hemmi H et al (2003) Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640–643 Yan M, Peng J, Jabbar IA et al (2004) Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324:297–310 Yan M, Peng J, Jabbar IA et al (2005) Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol 83:83–91 Yang R, Murillo FM, Delannoy MJ et al (2005) B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174:7912–7919 Yu L, Wang L, Li M et al (2010) Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 59:1021–1028 Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389–395 Zhang Y, Rassa JC, deObaldia ME et al (2003) Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein. J Virol 77:10468–10478 Zhou S, Kurt-Jones EA, Mandell L et al (2005) MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol 35:822–830 Zhu KJ, Cen JP, Lou JX et al (2009) Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. Int Immunopharmacol 9:412–417